<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04325711</url>
  </required_header>
  <id_info>
    <org_study_id>CSPCHA131-CSP-001</org_study_id>
    <nct_id>NCT04325711</nct_id>
  </id_info>
  <brief_title>A Study of CSPCHA131 in Patients With Advanced Solid Tumor</brief_title>
  <official_title>A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of CSPCHA131 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was designed to evaluate the safety, tolerability, pharmacokinetics, and
      preliminary antitumor activity of CSPCHA131 alone or plus chemotherapy in patients with
      advanced solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a dose escalation and expansion study with the aim to evaluate and characterize the
      tolerability and safety profile of CSPCHA131 alone (Stage I) or plus chemotherapy (Stage II)
      in patients with advanced solid tumors.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 12, 2020</start_date>
  <completion_date type="Anticipated">April 12, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 12, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) and incidence of dose limiting toxicity (DLT) within the first cycle at each dose level.</measure>
    <time_frame>Time Frame: 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs) and serious adverse events throughout the trial;</measure>
    <time_frame>from enrollment to the end of the trial (2 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) defined by RECIST Criteria Version 1.1;</measure>
    <time_frame>from enrollment to the end of the trial (2 years)</time_frame>
    <description>ORR is defined as the proportion of patients who achieve complete response (CR) or partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) defined by RECIST Criteria Version 1.1;</measure>
    <time_frame>from enrollment to the end of the trial (2 years)</time_frame>
    <description>PFS is defined as the time from the start of treatment until disease progression or death from any cause, whichever is earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>28 days</time_frame>
    <description>PK parameter: AUC0-t</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>28 days</time_frame>
    <description>PK parameter: AUC0-∞</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>28 days</time_frame>
    <description>PK parameter: Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Css_max</measure>
    <time_frame>28 days</time_frame>
    <description>PK parameter: Css_max</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Css_min</measure>
    <time_frame>28 days</time_frame>
    <description>PK parameter: Css_min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DF</measure>
    <time_frame>28 days</time_frame>
    <description>PK parameter: DF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ke</measure>
    <time_frame>28 days</time_frame>
    <description>PK parameter: Ke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>28 days</time_frame>
    <description>PK parameter: Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz</measure>
    <time_frame>28 days</time_frame>
    <description>PK parameter: Vz</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>28 days</time_frame>
    <description>PK parameter: T1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL</measure>
    <time_frame>28 days</time_frame>
    <description>PK parameter: CL</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>CSPCH131 dose Escalation and expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the dose escalation part of Stage I, five dose levels will be tested according to the &quot;3 + 3&quot; dose-escalation design. Whether and how to carry out the follow-up study parts will be decided by the PI and sponsor on the basis of the achieved results of safety, tolerability and effectiveness of CSPCHA131.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CSPCHA131</intervention_name>
    <description>CSPCHA131 will be administered twice weekly in the first three weeks of a 4-week cycle.</description>
    <arm_group_label>CSPCH131 dose Escalation and expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.18-75 years of age.

          -  2. Histologically or cytologically confirmed diagnosis of advanced or metastatic
             malignant solid tumors, for which standard therapy either does not exist or has been
             proven ineffective or intolerable for the patient.

          -  3. At least one measurable tumor lesion according to RECIST version 1.1.

          -  4. ECOG performance status of 0 or 1.

          -  5. Life expectancy ≥ 3 months. No cardiac insufficiency or serious abnormalities in
             the electrocardiogram at baseline.

        Exclusion Criteria:

          -  1. Administration of chemotherapy, radiotherapy, biotherapy, endocrine therapy,
             targeted therapy, immunotherapy, other anti-tumor treatments or an investigational
             drug within 4 weeks or 5 half-lives, whichever is longer, preceding the first dose of
             study treatment.

          -  2. Have undergone surgery within 4 weeks prior to the study treatment or have not
             fully recovered from any previous invasive procedure.

          -  3. Adverse reactions to previous anti-tumor treatments that levels have not recovered
             to grade 1 or less.

          -  4. Patients with evidence of uncontrolled nervous system metastasis or meningeal
             metastases, in the opinion of the investigator, not suitable for enrollment.

          -  5. Active infections of grade 2 or above.

          -  6. Peripheral neuropathy of grade 2 or above.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiugao Yang</last_name>
    <phone>+86 02160677906</phone>
    <email>yangxiugao@mail.ecspc.com</email>
  </overall_contact>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 10, 2020</study_first_submitted>
  <study_first_submitted_qc>March 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2020</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

